ALTHX — Thx Pharma SA Share News
0.000.00%
Last trade - 00:00Brief: Theranexus End-Dec Total Available Funds Stood At EUR 4.9 Mln
Brief: Theranexus Declares Encouraging Prelim Results For Batten Disease Drug
Brief: Theranexus And BBDF Granted Positive Opinion By EMA For Design Of Batten-1 Phase III Trial
Brief: Theranexus And BBDF Win FDA Approval On Endpoints For Phase III Trial To Evaluate Batten-1 In CLN3 Batten Disease
Brief: Alstrosight: Joint Project Between Theranexus, Inria, Claude Bernard University Lyon 1 And Hospices Civils De Lyon
Brief: Theranexus End-December Total Available Funds At 9.14 Mln Euros
Brief: Theranexus Announces Updates On Batten-1 Program With BBDF
Brief: Theranexus, Inserm Transfert Partner In Rare Neurological Diseases
Brief: Theranexus End-Q3 Available Funds Down At EUR 11.0 Mln
French and Benelux stocks-Factors to watch
Brief: Theranexus End-June Cash Position Of 11.6 Million Euros
Brief: Theranexus And The BBDF Foundation Finalize Enrollment For The Phase I/II Study Evaluating Batten-1 In Batten Disease
Brief: Theranexus End-June Available Funds At Eur 11.6 Mln
Brief: Theranexus FY Operating Income Down At EUR 25,000
Brief: Theranexus Aims To Start Pivotal Phase III Trials For Batten Disease At End Of 2022
Brief: Theranexus Initiates Recruitment For Phase I/II Study In Batten Disease With BBDF
French and Benelux stocks-Factors to watch
Brief: Theranexus End-December Available Cash At 12.5 Million Euros
Brief: Theranexus Implements New Equity Line For Maximum Sum Of 4.2 Million Euros